GEGANT
Live / Registered — Registered — international registration renewed (as of 13 Aug 2026)
What this means for you
Registered since 28 Apr 2020. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 28 Apr 2030: the §71 ten-year affidavit of use).
Record
- Serial number
- 79265476
- Registration number
- 6039395
- Mark type
- Word mark
- Filed
- 05 Jun 2019
- Published for opposition
- 11 Feb 2020
- Registered
- 28 Apr 2020
- Next maintenance filing
- §71 ten-year affidavit of use, due by 28 Apr 2030 (grace period to 28 Oct 2030)
- Attorney of record
- Kari Moyer-Henry
Goods and services
- Class 005 — Pharmaceuticals: Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing Gallium-68 for treating and diagnosing tumours; anti-cancer preparations, namely, Gallium-68 compounds, including 68-Ga chlorides; anti-cancer preparations, namely, Gallium-68 for use in the field of targeted radionuclide therapy of cancers, in particular prostate cancer and neuroendocrine tumours; cancer diagnostic preparations for medical purposes, namely, Gallium-68 compounds, including 68-Ga peptide chelates, in particular 68-Ga-Dotatoc and 68-Ga-Dotatate, 68-Ga salts, in particular 68-Ga chlorides; Gallium-68 for use as radiotracers in pet scans or combined PET/CT scans
- Class 010 — Medical apparatus: Medical apparatus and instruments for use in positron emission tomography (PET) imaging, namely, Ge-68/Ga-68 radionuclide generators for pharmaceutical purposes as source of radionuclides being positron emitters in the field of Positron Emission Tomography - Computed Tomography (PET/CT)
- Class 042 — Scientific and technological services: Scientific and technological services and research on radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, services relating to radiopharmaceuticals for the therapy and diagnosis of diseases and services relating to radiopharmaceuticals coupled to somatostatin analogues for the diagnosis and treatment of tumours, namely, scientific and product research and development
- Class 044 — Medical, beauty and agricultural services: Pharmaceutical advice in relation to radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, advice in relation to radiopharmaceuticals for the therapy and diagnosis of diseases, in particular tumour diseases, namely, pharmaceutical advice in relation to radiopharmaceuticals coupled to somatostatin analogues and advice in relation to the manufacture of personalised radiopharmaceutical products containing 68-Ga for use in medicine
Owner
Prosecution history
- 13 Aug 2026 — NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
- 13 Aug 2026 — REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
- 10 Aug 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 24 Apr 2026 — TEAS SECTION 71 & 15 RECEIVED
- 28 Apr 2025 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 26 Sept 2020 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 08 Sept 2020 — FINAL DISPOSITION NOTICE SENT TO IB
- 04 Sept 2020 — FINAL DISPOSITION PROCESSED
- 28 Jul 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 03 Jul 2020 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 28 Apr 2020 — REGISTERED-PRINCIPAL REGISTER
- 14 Feb 2020 — NOTIFICATION PROCESSED BY IB
- 11 Feb 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Feb 2020 — PUBLISHED FOR OPPOSITION
- 29 Jan 2020 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB